Teva Pharmaceutical Industries has won U.S. approval for Weltruza, a once-monthly olanzapine injection for adults with schizophrenia, opening a new treatment option that avoids the mandatory observation period attached to an older injectable version of the medicine.

Teva announced the Food and Drug Administration approval October 9 and expects U.S. availability in the coming weeks. The launch adds a second long-acting schizophrenia medicine to its partnership with French drug-delivery specialist Medincell, following the 2023 approval of risperidone injection Uzedy.

For patients and clinics, the distinction is practical. Olanzapine is already widely used as a daily pill, but converting it into a monthly treatment can reduce the burden of remembering medication every day. Clinics would also avoid setting aside several hours for observation after each dose of the older injection.

Weltruza is administered under the skin of the abdomen by a healthcare professional. It is not a self-injection. For patients who have not already demonstrated that they tolerate olanzapine, the prescribing information requires establishing tolerability with oral olanzapine before starting.

Once treatment begins, Weltruza does not require an additional loading dose or supplemental oral olanzapine. Teva plans to launch three strengths corresponding to established daily oral doses.

The older long-acting product, Zyprexa Relprevv, is injected into a muscle. Its FDA-required safety program restricts administration to certified healthcare settings and requires continuous observation for at least three hours after every injection.

Those safeguards address post-injection delirium/sedation syndrome, or PDSS, a reaction associated with unexpectedly high olanzapine exposure that can cause severe sleepiness, confusion and other overdose-like symptoms.

Weltruza does not carry that routine post-injection observation requirement. Its label nevertheless warns about PDSS, says no cases were reported in premarketing trials and states that the risk with Weltruza remains unknown.

That distinction is important: avoiding a required observation period does not mean the new treatment has no serious risks.

Approval followed the Phase 3 SOLARIS program. In its initial eight-week period, 675 adults were randomly assigned to one of three doses or placebo. Teva reported improvements in schizophrenia symptoms, illness severity, and personal and social functioning.

In a previously published long-term SOLARIS analysis, Teva reported no suspected or confirmed PDSS events across 3,470 injections. The absence of an event in a trial cannot rule out a rare reaction after broader use.

The company reported weight gain, sleepiness, headache, constipation and injection-site reactions among commonly observed adverse events. The overall safety findings were consistent with olanzapine’s established profile.

Ongoing clinical monitoring remains necessary. The prescribing information addresses weight gain, high blood sugar and changes in blood fats, including recommendations for glucose, lipid and weight assessments.

Weltruza also carries a boxed warning, the FDA’s strongest label warning, about increased mortality in elderly patients with dementia-related psychosis. It is not approved for that condition.

The commercial opportunity is substantial, but access will depend on more than regulatory approval. On its October 9 investor call, Teva set the wholesale acquisition cost at $3,950 per monthly dose.

At that price, 12 injections would total $47,400 before rebates, discounts or administration costs. Wholesale acquisition cost is a list-price measure, not the amount every patient or insurer ultimately pays.

Teva estimated on the call that about 1.5 million Americans are being treated for schizophrenia and roughly 20% take oral olanzapine. That implies approximately 300,000 treated patients using the oral medicine, rather than 300,000 people automatically eligible or expected to switch.

The company plans to build on the commercial capabilities developed for Uzedy. For Teva, long-acting branded medicines are part of its effort to expand beyond the generic-drug business for which it is best known.

For families, the potential benefit is a simpler medication schedule. A monthly injection still requires reliable clinic visits, a treatment plan suited to the individual and attention to side effects. The National Institute of Mental Health also emphasizes that medication is commonly combined with psychological, employment and family-support services.

The immediate milestones are U.S. launch and coverage decisions. European review remains separate: Teva said the European Medicines Agency accepted its application in May 2026, but the medicine had not received European approval in its October 9 announcement.

JBizNews Desk | Washington

© JBizNews.com. All rights reserved. This article is original reporting by JBizNews Desk. Unauthorized reproduction or redistribution is strictly prohibited.